TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 13nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 10nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 365nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 6nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 307nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 34nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 53nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair
TargetProtein O-GlcNAcase(Homo sapiens (Human))
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Alectos Therapeutics Inc.; Merck Sharp & Dohme Corp.
US Patent
Affinity DataEC50: 358nMT: 2°CAssay Description:The ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4° C. with 100 uL/well of the cell ly...More data for this Ligand-Target Pair